Breast health

HRT and Breast Density: What Changes on Imaging

Combined hormone therapy can increase breast density on mammograms, making abnormalities harder to detect and slightly lowering screening accuracy. Estrogen-alone therapy affects density less. Roughly 40 to 50 percent of women already have dense breasts, and hormone therapy can add to that. The effect usually eases within months of stopping.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

How does hormone therapy change breast density?

Estrogen and progestogen stimulate glandular tissue in the breast, which appears as white, dense areas on a mammogram. According to the National Cancer Institute, menopausal hormone therapy — especially the combined estrogen-progestogen form — can increase breast density, and dense tissue shows up the same white color as many tumors 1Ref 1National Cancer Institute (PDQ Screening and Prevention Editorial Board) (2025).Breast Cancer Screening.NCI patient guidance that menopausal hormone therapy increases mammographic breast density, that dense tissue lowers mammogram sensitivity and slightly raises breast-cancer risk, and that supplemental imaging is an option for dense breasts..

Density is scored on a four-category scale, and roughly 40 to 50 percent of screened women fall into the two denser categories 1Ref 1National Cancer Institute (PDQ Screening and Prevention Editorial Board) (2025).Breast Cancer Screening.NCI patient guidance that menopausal hormone therapy increases mammographic breast density, that dense tissue lowers mammogram sensitivity and slightly raises breast-cancer risk, and that supplemental imaging is an option for dense breasts.. Breasts tend to be densest in younger and perimenopausal women and grow less dense across the menopause transition, so hormone therapy adds its effect on top of that shifting baseline 1Ref 1National Cancer Institute (PDQ Screening and Prevention Editorial Board) (2025).Breast Cancer Screening.NCI patient guidance that menopausal hormone therapy increases mammographic breast density, that dense tissue lowers mammogram sensitivity and slightly raises breast-cancer risk, and that supplemental imaging is an option for dense breasts.. Estrogen-alone therapy generally raises density less than the combined form 1Ref 1National Cancer Institute (PDQ Screening and Prevention Editorial Board) (2025).Breast Cancer Screening.NCI patient guidance that menopausal hormone therapy increases mammographic breast density, that dense tissue lowers mammogram sensitivity and slightly raises breast-cancer risk, and that supplemental imaging is an option for dense breasts..

Does denser tissue make a mammogram harder to read?

Denser breast tissue lowers the sensitivity of a standard mammogram, so some cancers are missed that would show up in fatty breasts. According to the National Cancer Institute, a mammogram finds most but not all breast cancers, and its accuracy falls as density rises 1Ref 1National Cancer Institute (PDQ Screening and Prevention Editorial Board) (2025).Breast Cancer Screening.NCI patient guidance that menopausal hormone therapy increases mammographic breast density, that dense tissue lowers mammogram sensitivity and slightly raises breast-cancer risk, and that supplemental imaging is an option for dense breasts..

Because combined hormone therapy can push density higher, a woman using it may sit in a category where the test is a little less reliable 1Ref 1National Cancer Institute (PDQ Screening and Prevention Editorial Board) (2025).Breast Cancer Screening.NCI patient guidance that menopausal hormone therapy increases mammographic breast density, that dense tissue lowers mammogram sensitivity and slightly raises breast-cancer risk, and that supplemental imaging is an option for dense breasts.. Dense tissue also modestly raises breast-cancer risk on its own, independent of any medication 1Ref 1National Cancer Institute (PDQ Screening and Prevention Editorial Board) (2025).Breast Cancer Screening.NCI patient guidance that menopausal hormone therapy increases mammographic breast density, that dense tissue lowers mammogram sensitivity and slightly raises breast-cancer risk, and that supplemental imaging is an option for dense breasts.. Newer 3D mammography, called tomosynthesis, improves detection somewhat, and the American College of Obstetricians and Gynecologists describes supplemental ultrasound as an option some women with dense breasts consider 2Ref 2American College of Obstetricians and Gynecologists (2017).Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women.ACOG breast-cancer screening guidance for average-risk women, including recommended starting age and interval and the role of supplemental imaging in dense breasts..

How much does hormone therapy raise breast-cancer risk?

Combined estrogen-progestogen therapy carries a small, real increase in breast-cancer risk that grows with duration of use. In the Women's Health Initiative, combined therapy was linked to a modestly higher risk after 3 to 5 years, while estrogen-alone therapy was associated with a lower risk in women without a uterus 3Ref 3Chlebowski RT, Anderson GL, Aragaki AK, et al. (2020).Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials.WHI long-term analysis showing combined estrogen-progestogen therapy modestly raises breast-cancer incidence with duration, while estrogen-alone therapy was associated with lower incidence..

The Million Women Study, a large cohort, found a similar rise in risk with combined regimens 4Ref 4Beral V / Million Women Study Collaborators (2003).Breast cancer and hormone-replacement therapy in the Million Women Study.Million Women Study cohort showing increased breast-cancer risk with combined hormone-replacement regimens.. The North American Menopause Society frames the absolute increase as on the order of fewer than 1 extra case per 1,000 women a year for many users, and notes the risk recedes after stopping 5Ref 5The North American Menopause Society (Menopause Society) (2022).The 2022 Hormone Therapy Position Statement of The North American Menopause Society.NAMS 2022 position statement framing the absolute breast-cancer risk of hormone therapy and noting the risk recedes after stopping.. Density and cancer risk are related but separate concerns, and both feed into how screening is planned 1Ref 1National Cancer Institute (PDQ Screening and Prevention Editorial Board) (2025).Breast Cancer Screening.NCI patient guidance that menopausal hormone therapy increases mammographic breast density, that dense tissue lowers mammogram sensitivity and slightly raises breast-cancer risk, and that supplemental imaging is an option for dense breasts..

Should you time or adjust screening around hormone therapy?

Screening plans can be personalized when hormone therapy is part of the picture, though the core recommendation stays the same. The American College of Obstetricians and Gynecologists recommends that average-risk women be offered mammograms starting by age 40, typically every 1 to 2 years 2Ref 2American College of Obstetricians and Gynecologists (2017).Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women.ACOG breast-cancer screening guidance for average-risk women, including recommended starting age and interval and the role of supplemental imaging in dense breasts..

Density often rises in the first year of combined therapy and then stabilizes, so a baseline mammogram and consistent yearly comparison images help radiologists spot subtle change 1Ref 1National Cancer Institute (PDQ Screening and Prevention Editorial Board) (2025).Breast Cancer Screening.NCI patient guidance that menopausal hormone therapy increases mammographic breast density, that dense tissue lowers mammogram sensitivity and slightly raises breast-cancer risk, and that supplemental imaging is an option for dense breasts.. Women with dense breasts may discuss supplemental ultrasound or MRI, especially alongside other risk factors, and those wondering about the right screening ages can compare recommendations 2Ref 2American College of Obstetricians and Gynecologists (2017).Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women.ACOG breast-cancer screening guidance for average-risk women, including recommended starting age and interval and the role of supplemental imaging in dense breasts.. If hormone therapy is stopped, density and mammographic clarity usually improve within a few months 1Ref 1National Cancer Institute (PDQ Screening and Prevention Editorial Board) (2025).Breast Cancer Screening.NCI patient guidance that menopausal hormone therapy increases mammographic breast density, that dense tissue lowers mammogram sensitivity and slightly raises breast-cancer risk, and that supplemental imaging is an option for dense breasts..

When dense breasts need a tailored screening plan

Persistent questions about dense breasts and hormone therapy are worth a dedicated conversation with a clinician. A clinician who prescribes or manages your hormone therapy can weigh your symptom relief against your personal breast-cancer risk and screening history.

Bring your most recent mammogram report, any note about breast density, and questions about supplemental imaging. If you are weighing whether to start, continue, or stop therapy, that decision belongs with someone who knows your full history. You can also review what age women should get a mammogram and how to check breasts for lumps between visits. Gale can help you prepare for that conversation.

Common questions

It can. Combined estrogen-progestogen therapy tends to increase breast density, and denser tissue lowers a mammogram's ability to detect small cancers. The effect is usually modest, and radiologists account for it by comparing images year to year. Many women on hormone therapy still screen effectively, sometimes with the help of 3D mammography or supplemental ultrasound.

Usually not. Mammographic density that rises with combined hormone therapy tends to decrease within a few months of stopping. Baseline density is also shaped by age, genetics, and body composition, so it settles toward your natural pattern rather than to a specific number.

Estrogen-alone therapy, used by women who have had a hysterectomy, generally raises density less than combined therapy and has not been linked to the same increase in breast-cancer risk. Whether it fits depends on your health history and whether you still have a uterus, which a clinician can review.

Possibly. Some women with dense breasts consider supplemental ultrasound or MRI in addition to mammography, particularly when other risk factors are present. There is no single rule that fits everyone, so the decision is individualized with your clinician and often your radiologist.

Breast health
Dense Breasts: Decoding Your Notification Letter
Breast health
Mammogram Benefits and Harms: An Honest Ledger
Breast health
What Mammograms Can Miss and Why

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When breast changes need prompt evaluation

—A new breast lump, skin dimpling, or nipple change while on hormone therapy is a reason to seek clinician review, not a wait-and-see.
—Bloody or spontaneous one-sided nipple discharge is a reason to seek clinician review.
—A mammogram report that recommends additional imaging is a reason to schedule the follow-up promptly.
—A personal or strong family history of breast cancer is a reason to review your hormone therapy and screening plan with a specialist.

This article is general health education, not medical advice. Whether hormone therapy is right for you and how to screen around it are decisions to make with a gynecologist or menopause clinician who knows your history.

References

1.National Cancer Institute (PDQ Screening and Prevention Editorial Board) (2025). Breast Cancer Screening. National Cancer Institute (NCI), NIH. link ✓NCI patient guidance that menopausal hormone therapy increases mammographic breast density, that dense tissue lowers mammogram sensitivity and slightly raises breast-cancer risk, and that supplemental imaging is an option for dense breasts.
2.American College of Obstetricians and Gynecologists (2017). Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women. Obstetrics & Gynecology. doi:10.1097/AOG.0000000000002158 ✓ACOG breast-cancer screening guidance for average-risk women, including recommended starting age and interval and the role of supplemental imaging in dense breasts.
3.Chlebowski RT, Anderson GL, Aragaki AK, et al. (2020). Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. JAMA. doi:10.1001/jama.2020.9482 ✓WHI long-term analysis showing combined estrogen-progestogen therapy modestly raises breast-cancer incidence with duration, while estrogen-alone therapy was associated with lower incidence.
4.Beral V / Million Women Study Collaborators (2003). Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. doi:10.1016/s0140-6736(03)14065-2 ✓Million Women Study cohort showing increased breast-cancer risk with combined hormone-replacement regimens.
5.The North American Menopause Society (Menopause Society) (2022). The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. doi:10.1097/GME.0000000000002028 ✓NAMS 2022 position statement framing the absolute breast-cancer risk of hormone therapy and noting the risk recedes after stopping.

5 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library